genedrive plc (LON:GDR – Get Free Report)’s share price shot up 4.3% during trading on Wednesday . The stock traded as high as GBX 2.40 ($0.03) and last traded at GBX 2.40 ($0.03). 1,421,360 shares traded hands during mid-day trading, a decline of 90% from the average session volume of 14,291,111 shares. The stock had previously closed at GBX 2.30 ($0.03).
genedrive Price Performance
The company has a market cap of £13.04 million, a P/E ratio of -57.50 and a beta of -0.04. The stock has a 50-day simple moving average of GBX 2.27 and a 200 day simple moving average of GBX 2.74. The company has a debt-to-equity ratio of 8.57, a quick ratio of 5.52 and a current ratio of 1.63.
Insider Buying and Selling
In other genedrive news, insider Ian David Gilham purchased 1,000,000 shares of the stock in a transaction on Wednesday, August 14th. The shares were purchased at an average price of GBX 3 ($0.04) per share, with a total value of £30,000 ($38,905.46). 14.75% of the stock is owned by company insiders.
About genedrive
genedrive plc, a molecular diagnostics company, engages in developing and commercializing point of need diagnostics platform for infectious diseases, genotyping, pathogen detection, and other indications. The company provides Genedrive system, a rapid thermocycler and signal detection system and semi- automated system used forqualitative in vitro molecular diagnostic tests; and Genedrive CYP2C19 ID Kit, a point-of-care test for rapid CYP2C19 genotyping in time-critical emergency care settings.
Featured Stories
- Five stocks we like better than genedrive
- How to Start Investing in Real Estate
- 3 ETFs With Low Fees and Market-Beating Returns
- 3 Monster Growth Stocks to Buy Now
- Inflation Threats Make Yield Curve ETFs a Top Trade
- The Risks of Owning Bonds
- Double-Digit Gains Ahead? Top 2 Stocks Positioned to Outperform
Receive News & Ratings for genedrive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for genedrive and related companies with MarketBeat.com's FREE daily email newsletter.